Navigation Links
Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock

Plan Ahead(TM) Test Offers Most Accurate Measurement of Women's Ovarian


ATLANTA, Jan. 21 /PRNewswire/ -- Georgia Reproductive Specialists (GRS) today announced it will be the first IVF center in the southeast to offer the Repromedix Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors, including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs, which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.

The Plan Ahead Report provides valuable directional information about which women planning to have children after their late twenties should seek further advice from fertility experts to help ensure that those women with faster biological clocks can have the families they were hoping for.

"GRS has always incorporated the latest assisted reproductive technologies (ART) into our treatment plans to give our patients the best chance possible of having a baby, said Mark Perloe, M.D., Medical Director of Georgia Reproductive Specialists. "We strive to provide our patients with the most advanced testing and treatment options, so it is most appropriate that GRS is the first IVF center in the Southeast to offer the Plan Ahead test."

As women age, their fertility naturally declines, with increasingly fewer eggs available for fertilization. "With so many women delaying pregnancy until their 30s and 40s, women urgently need an accurate assessment of their egg supply," said Dr. Perloe. "And while we know that on average ovarian reserve begins a more rapid decline after age 35, it varies among women of the same age. The Plan Ahead test will provide women with the individual assessment of their own ovarian reserve to help them make more informed decisions about when to have a child. We're pleased to be in the vanguard of this critical new test."

"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer of Repromedix Corp. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."

Repromedix Corp., the Plan Ahead test co-developer and leading national diagnostic laboratory for fertility testing, chose GRS to be one of a select number of IVF centers to debut the test. Repromedix will expand the Plan Ahead test launch to major markets across the United States throughout 2008.

Plan Ahead is now available to women in the greater Atlanta area, and women interested in the Plan Ahead test can purchase a test online at or at Georgia Reproductive Specialists, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the Plan Ahead test is $350. Women interested in learning more about Plan Ahead, should visit:

About Georgia Reproductive Specialists (

Georgia Reproductive Specialists (GRS), founded in 2000, applies medical science's most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies.

About Repromedix (

Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.

Contact: Lisa Hester, Rountree Group

770-645-4545 Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Julie Dennehy

SOURCE Repromedix
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pioneer in Reproductive Medicine Opens The Countrys First Comprehensive Fertility Practice
2. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
3. Specialists in infectious disease and global health convene at Philadelphia meeting
4. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
5. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
6. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
7. Stemagen First to Create Cloned Human Embryos From Adult Cells
8. Peptimmune Announces First Close of Series D Private Financing
9. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
10. Pharmaxis Aridol Gains First Asian Approval
11. Society for Biological Engineering Holds First International Conference on Stem Cell Engineering
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
Breaking Biology News(10 mins):